N. Fodil, E. Del Cid-Pellitero, V. E.-C. Piscopo, J. Xiao Xuan Luo, M. Wong, J. F. Olivier, A. Alluli, I. Shlaifer, Z. You, C. X.-Q. Chen, N. Aprahamian, Y. Cha, E. Colette, J. Mayo, A. Annett, N. Jabado, C. L. Kleinman, M. N. Kagalwala, J. Ross, M. Lathrop, D. Langlais, T. M. Durcan, E. A. Fon, P. Gros
Neuroinflammation strongly contributes to the pathogenesis of neurological and neurodegenerative diseases, including Parkinson's disease. We show that ablation of Usp15 in astrocytes and in microglia protects against lethal neuroinflammation in vivo. In a mouse model of synucleinopathy, Usp15 deletion diminishes alpha-syn deposits in the brain, slows disease progression, and increases survival time. The neuroprotective effect of Usp15 is associated with differential expression of inflammatory pathways in situ including interferon stimulated genes. These USP15-dependent effects in vivo are recapitulated in vitro in primary human microglia and astrocytes. We detect high USP15 expression in microglia from Parkinson's patients with strong co-expression with LRRK2 and SNCA. In humans, we detect a strong cis-acting eQTL directing high USP15 expression in CD14+ myeloid cells. The allele driving this eQTL is itself associated with increased disease risk, linking myeloid USP15 expression, elevated USP15 plasma levels in Parkinson's patients, to genetic susceptibility.